Juan C Ramos MD

Hematology•Miami, FL

Hematologic Oncology

Professor, Medicine, University of Miami School of Medicine

Join to View Full Profile

1611 NW 12th Ave# M851Miami, FL 33136
Phone+1 305-243-1000
Fax+1 305-243-9927

Education & Training

University of Miami/Jackson Health SystemResidency, Internal Medicine, 1999 - 2001
Rutgers New Jersey Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2003 - 2027

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2008 Sep 01
Terminated
Phase 1
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma Start of enrollment: 2007 Nov 01
Terminated
Phase 4
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Start of enrollment: 2013 Nov 01
Terminated
Phase 1
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
Completed
Phase 2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Start of enrollment: 2009 Apr 21
Terminated
Phase 2
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias Start of enrollment: 2023 Nov 30
Withdrawn
Phase 1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Trial of Ixazomib for Kaposi Sarcoma Start of enrollment: 2023 Nov 07
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

MIRD Pamphlet No. 32: A MIRD Recovery Coefficient Model for Resolution Characterization and Shape-Specific Partial-Volume Correction.
Harry Marquis, C Ross Schmidtlein, Robin de Nijs, Pablo Mínguez Gabiña, Johan Gustafsson
Journal of Nuclear Medicine. 2025-03-03
Transcriptome and microbiome-immune changes across preinvasive and invasive anal cancer lesions.
Ezequiel Lacunza, Valeria Fink, María E Salas, Ana M Gun, Jorge A Basiletti
JCI Insight. 2024-07-18
2 citations
Unveiling the role of KSHV-infected human mesenchymal stem cells in Kaposi's sarcoma initiation.
Ezequiel Lacunza, Anuj Ahuja, Omar A Coso, Martin Abba, Juan Carlos Ramos
Journal of Medical Virology. 2024-05-01

Abstracts/Posters

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Stu...
Juan Carlos Ramos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
Juan Carlos Ramos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Sylvester Cancer Tip Sheet: Researchers Present Posters at the 66th ASH Annual Meeting & ExpositionNovember 13th, 2024
Sylvester Cancer Tip Sheet: Researchers Present Posters at the 66th ASH Annual Meeting & ExpositionNovember 13th, 2024